My friends Today Tiresias presumes to review his predictions....

My friends

Today Tiresias presumes to review his predictions. This is a dangerous thing. Tiresias is wary of hubris. He is wary of presumption, arrogance, and the sin of pride. He does not wish for a visitation from that daughter of Erebus and Nyx. Nevertheless, it is important to look back so as to more clearly see forward.

When Tiresias was first inspired to write a small epistle on Optiscan, the company was priced for failure. It was truly “The winter of our discontent.” As Tiresias saw, and in addressing the naysayers, foresaw, Optiscan has survived. Since then, there have been changes and developments. Most importantly, Optiscan has been refinanced with AUD$10 placement to Clermont Group of Richard Chandler, and Orchid Group of other Singapore investors. Mr Ron Song, a very experienced businessman, with commercial, health, and financial networks in Australia and Asia, has joined the board. We see an immediate change in the half-yearly report. Clermont Group is yet to nominate another member to the board. There is great progress in trials in oral cancer, breast cancer, Carl Zeiss in neurosurgery and other cancers and applications coming up. Optiscan share price has responded. Tiresias sees that it is no longer priced for failure. It is merely priced for survival. Tiresias sees a rapid revaluation and pricing for success. Real transformative success. Now is the time for a just a little patience. The pricing for real success will come soon enough. Tiresias’s friends know that share prices do not go up vertically. The weak hands have to be flushed out. Many of the stale nervous legacy holders have sold out already. This is good and this ensures a stronger rise. There will still be some now who are quivering with excitement at the current share price. Some of these will sell. That is also good. Tiresias however, would counsel his friends to remain cool and enjoy the ride. Tiresias is still relaxed but avoiding any suggestion of excitement or hubris.